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A B S T R A C TObjectives: To examine and compare the two utility and health-related
quality-of-life (HRQOL) measures 15D and (SF-6D) in fragility wrist and
hip fracture patients and controls, study the responsiveness of 15D and
SF-6D, and examine the impact of these fractures on changes in 15D and
SF-6D scores over 2 years.Methods: A total of 152 wrist fracture patients
and 164 controls and 61 hip fracture patients and 61 controls with 15D
and SF-6D scores were studied. Results: The mean 15D score decreased
significantly in wrist fracture patients between baseline and 2-year
follow-up (P ¼ 0.003). A wrist fracture was a significant predictor of a
decrease in 15D scores 2 years after fracture (B ¼ 0.016; P ¼ 0.049),
along with low body mass index (B ¼ 0.002; P ¼ 0.009). In hip fracturent matter Copyright & 2012, International Society
r Inc.
.1016/j.jval.2012.08.2200
ohde@sshf.no.
ondence to: Gudrun Rohde, Department of Rheum
ay.patients, both 15D and SF-6D scores decreased significantly (Po 0.001).
A hip fracture was a significant predictor of a decrease in 15D
(B ¼ 0.060; P ¼ 0.001) and SF-6D (B ¼ 0.096; P ¼ 0.001) scores. Conclu-
sions: Our data suggest that a fragility wrist fracture has a long-term
negative effect on HRQOL, but not as strong as for fragility hip fractures.
15D seems to be more responsive than SF-6D when assessing HRQOL in
patients with fragility fractures.
Keywords: decision making, 15D, health-related quality of life, SF-36,
osteoporosis.
Copyright & 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Fragility fractures may be devastating for the individual, challenging
for the health care system due to the increased demand of health
care, and a burden to society because of increased costs [1]. The most
frequent sites for nonvertebral fragility fractures are wrist and hip.
Previous studies have consistently reported that patients with a
fragility fracture at hip experience a long-term negative impact on
health-related quality of life (HRQOL) and the patients do not regain
prefracture HRQOL levels [2–6]. For fragility wrist fracture, however,
several studies indicate no long-term negative effects on HRQOL [7–9].
HRQOL can be used for economic evaluation (cost-utility
analysis), and several generic utility instruments (e.g., 15D, six-
dimensional health state short form [derived from short form
36 health survey (SF-36)] [SF-6D], and EuroQol five-dimensional
[EQ-5D] questionnaire) have been developed. The underlying idea
is that the utility (value) of a health state can be measured on a
scale from death (0.0) to perfect health (1.0). Such utility mea-
sures can also be used to calculate quality-adjusted life-years
[10,11]. The ability of the instruments to detect clinically impor-
tant differences and changes is vital to their usefulness and
applicability in clinical practice. This ability may be assessed by
exploring the responsiveness of the instruments, which may be
considered as one form of validity [12,13].There is a general lack of knowledge regarding changes in HRQOL
in patients with fragility fractures compared with individuals from
the general population, in particular as assessed by utility instru-
ments [2,11]. Apart from two studies, no previous studies of patients
with fragility fractures have compared results from utility-measures
with those of other generic HRQOL measures such as SF-36 [2,14].
From a prospective case-control study, we have recently pub-
lished long-term SF-36 (HRQOL) data in patients with fragility wrist
and hip fracture, reporting long-term reduction in SF-36 HRQOL in
hip fracture patients after 2 years [15] but no long-term reduction
in SF-36 HRQOL in patients with wrist fracture after 1 year [9].
From this same study population of wrist and hip fracture
patients and controls, we aimed to examine and compare the two
utility measures 15D and SF-6D. Furthermore, our aim was to
study the responsiveness of 15D and SF-6D and examine the
impact of a fragility wrist or hip fracture on changes in 15D and
SF-6D scores after 1 and 2 years.Methods
Study Population and Data Collection
Patients aged 50 years and older with fragility wrist or hip fractures
attending a regional hospital in the southern part of Norway in afor Pharmacoeconomics and Outcomes Research (ISPOR).
atology, Sorlandet Hospital, Kristiansand, Servicebox 416, 4604
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 1 0 0 – 1 1 0 7 11012-year period were invited to the Osteoporosis Center for assess-
ment of bone mineral density (BMD) and health status and
participation in a 2-year prospective case-control study. The con-
trols were recruited consecutively from the same geographic area.
Patients with confusion or dementia, serious infection, patients not
capable of giving informed consent, patients unable to speak
Norwegian, and tourists were excluded. Study design, data collec-
tion, and demographic, clinical, bone density, and SF-36 (HRQOL)
data from this study have previously been described in detail
[9,16,17]. For the wrist fracture patients, only 1-year follow-up data
have been published previously [9]. In our study, wrist fracture, also
called distal radius fracture in the literature, was defined as a
fracture located within 3 cm of the radiocarpal joint.
In the 2-year inclusion period, 324 patients with fragility wrist
fractures were treated at the hospital, and 249 of these patients were
clinically examined at the Osteoporosis Center (30 patients were
excluded, and 45 declined BMD assessment). Of the 249 patientswith
wrist fractures examined at the Osteoporosis Center, 181 met the
inclusion criteria and were willing to enroll in this study (21 patients
were excluded, and 47 were unwilling to participate), yielding a
response rate of 66%. At 1-year follow-up, data were available for 160
patients (21 dropped out) and 169 controls [9] and at 2-year follow-up
for 152 patients (17 dropped out) and 164 controls.
Four hundred fifty-six patients with fragility hip fracture were
treated at the hospital. Among them, 307 patients were clinically
examined at the Osteoporosis Center (137 patients were
excluded, and 12 declined BMD assessment). Of the 307 patients
with hip fractures examined at the Osteoporosis Center, 97 met
the inclusion criteria and were willing to enroll in this prospec-
tive study (134 patients were excluded, and 76 were unwilling to
participate), yielding a response rate of 52%. Among the hip
fracture patients, 72 patients had 1-year data (5 died and 20
dropped out) and 61 patients had 2-year data (5 died, and 6
dropped out) [15]. The 61 patients with a hip fracture who were
still in the study at 2-year follow-up were age and sex matched
with 61 of the controls (5 years) who had valid measures at
baseline and at 1- and 2-year follow-up [15].
At baseline, the patients were asked to report their status
prior to fracture and the controls were asked to report their status
at the time prior to inclusion. With regard to the 15D question-
naire, the patients were asked to report their HRQOL at the time
before fracture and the controls at the time before inclusion, and
for SF-36 the 4 weeks before fracture for patients and the 4 weeks
before inclusion for the controls. The same data collection
performed at baseline was repeated after 1 and 2 years.
The collected data included demographical and clinical data,
exercise (more than 30 minutes three times a week), smoking
habits, medication, previous fragility fractures after the age of 50
years, number of falls the year before the fracture, and comorbidity
(heart diseases, pulmonary diseases, neurological disorders, urogen-
ital disorders, gastrointestinal disorders, endocrine disorders,
inflammatory joint disorders and connective tissue disorders, can-
cer, mental disorders) as listed in Table 1. For comorbidity, we also
computed a sum score of the number of diseases for each patient.
BMD was measured at femoral neck, total hip, and lumbar
spine (L2–4) by using the same dual-energy X-ray absorptiometry
equipment (General Electric, Lunar Prodigy) previously described
in detail [9]. Osteoporosis was defined as a T score ofr2.5 SD,
osteopenia as a T score of42.5 and o1.0, and normal BMD as
a T score of41.0, according to the World Health Organization
definition for osteoporosis [18].
The Utility Measures 15D and SF-6D
The 15D questionnaire is a generic, multidimensional, standardized
evaluation tool of HRQOL that can be primarily used as a single
index measure but also as a profile utility measure. It describes thehealth status, assessing the following 15 dimensions: mobility,
vision, hearing, breathing, sleeping, eating, speech, elimination,
usual activities, mental function, discomfort and symptoms,
depression, distress, vitality, and sexual activity [19]. Each dimen-
sion comprises one question with five response categories. A single
utility index score is obtained by incorporating population-based
preference weights into the dimensions. The algorithm has been
developed on the basis of multiattribute utility theory, and the 15D
weights are based on a Finnish study from 2001 [19]. The algorithm
has also been used in Norwegian studies [20,21]. The utility scores
fall between 0.0 (being dead) and 1.00 (no problems on any
dimension). Regression analyses were performed to impute missing
values. The questionnaire has been thoroughly tested for psycho-
metric properties in other studies within several countries [19–21].
The SF-6D is a utility instrument in which SF-36 or SF-12 scores
can be translated into this utility score by means of an algorithm
based on a standard gamble technique [10]. The SF-6D is based on 11
questions from the SF-36 and includes six dimensions, each with
four to six levels. The SF-6D utility scores range from 0.29 to 1.00,
with 1.00 indicating ‘‘full health.’’ The Norwegian standard SF-36 v.
1.00 was used to derive the SF-6D. The different health states are
assigned values derived from valuations of SF-6D health status
using standard gamble in a representative sample of the UK
population. Regression analyses were performed to impute missing
values. The questionnaire has been tested for psychometric proper-
ties in other studies in several countries [10].
Statistical Analysis
Statistical analyses were carried out by using the Statistical
Package for Social Sciences for Windows (version 18.0). Chi-
square tests and t tests were used to compare differences
between subgroups. Paired samples t tests were used to compare
changes in 15D and SF-6D scores between baseline and 1-year
follow-up, and between baseline and 2-year follow-up, within
each patient group and within controls. General linear model
(repeated multivariate analysis of variance) was also applied to
examine differences in the repeated HRQOL measures within the
groups [12,22]. Mean 15D and SF-6D change scores (SD) over the
2-year period were calculated within the groups. Independent
sample t tests were used to compare differences in 15D and SF-6D
scores between patients and controls at baseline and at 1- and 2-
year follow-up. Pearson correlation coefficients between 15D and
SF-6D 2-year change scores were calculated.
To examine the internal responsiveness of the instruments,
the observed change and effect size (ES) related to the change in
the 15D and SF-6D scores were calculated within patients and
within controls. ESs were calculated by subtracting the mean 15D
and SF-6D scores at inclusion from the mean scores of the 1- and
2-year follow-up and then dividing by each group’s SD at inclu-
sion [23]. We applied Cohen standards for ESs as follows: small
effect, 0.2; medium effect, 0.5; and large effect, 0.8 [22].
Multiple linear regression analysis (procedure general linear
model in the Statistical Package for Social Sciences) was used to
examine the impact of a fragility wrist or hip fracture on 2-year
changes in the 15D and SF-6D scores. Independent variables in
the multiple regression analyses were the demographic variables
of age, gender, and marital status (cohabiting/living alone) and
the clinical variables of BMD (normal BMD/osteopenia/osteoporo-
sis) and patients/controls. These variables showed correlations
with the patients/controls dichotomy at baseline and have been
shown to be covariates of HRQOL in earlier studies [12]. The
regression analyses were adjusted for 15D or SF-6D scores at
baseline. To test whether the effects of independent variables in
the regression models (potential predictors of change) on our
dependent variables were significantly different for patients
and controls, interaction terms involving the patient/control
Table 1 – Baseline demographical and clinical characteristics in patients with wrist fracture and controls and in patients with
hip fractures and controls who visited the osteoporosis center both at baseline and at 2-y follow-up.
Wrist fracture Controls P* Hip fracture Controls P†
(n ¼ 152) (n ¼ 164) (n ¼ 61) (n ¼ 61)
Demographics
Age (y), mean  SD 67  9 66  9 0.588 74  10 73  8 0.502
Females 136 (90) 147 (90) 0.963 46 (75) 46 (75) 1.00
BMI (kg/m2) 25.7 (4.4) 26.7 (4.4) 0.049 23.6 (3.7) 26.8 (3.7) o0.001
Menarche (y), mean  SD 13.9  1.5 13.6  1.4 0.089 14.3  1.9 13.7  1.1 0.064
Menopause (y), mean  SD 49.0  4.5 49.6  4.1 0.277 48.3  5.6 50.0  3.4 0.090
Education 0.008 0.525
o10 y 50 (36) 68 (42) 26 (46) 22 (37)
11–13 y 60 (43) 43 (26) 18 (32) 21 (35)
413 y 30 (21) 52 (32) 12 (21) 17 (28)
Cohabiting 82 (54) 111 (68) 0.012 26 (44) 38 (62) 0.045
Regular exercisez 113 (74) 123 (75) 0.893 36 (59) 47 (77) 0.033
Current smoker 22 (15) 20 (12) 0.551 16 (36) 6 (10) 0.019
Clinical characteristics
Current calcium and/or vitamin D treatment 36 (24) 40 (24) 0.909 12 (20) 18 (30) 0.207
Current ART 26 (17) 26 (15) 0.653 9 (15) 10 (16) 0.803
Previous fractures 79 (52) 75 (47) 0.337 28 (46) 29 (48) 0.362
Z1 fall in the previous year 62 (46) 47 (36) 0.118 27 (47) 19 (37) 0.289
Osteoporosis spine/hipy 48 (32) 28 (18) o0.001 35 (58) 12 (20) 0.001
Femoral neck: 0.001 0.023
Normal BMD 20 (14) 49 (31) 6 (20) 13 (23)
Osteopenia 80 (56) 82 (52) 7 (23) 28 (49)
Osteoporosis 42 (30) 28 (17) 17 (57) 16 (28)
Total hip: o0.001 o0.001
Normal BMD 32 (21) 73 (45) 5 (9) 21 (36)
Osteopenia 92 (62) 71 (44) 24 (43) 30 (51)
Osteoporosis 25 (17) 18 (11) 27 (48) 8 (14)
Lumbar spine L2–4: o0.001 0.018
Normal BMD 25 (16) 62 (38) 19 (31) 31 (52)
Osteopenia 79 (52) 72 (44) 19 (31) 19 (31)
Osteoporosis 48 (32) 29 (18) 23 (28) 10 (17)
Heart diseases 45 (30) 57 (35) 0.328 28 (48) 30 (49) 0.856
Pulmonary diseases 18 (12) 12 (7) 0.170 10 (16) 5 (8) 0.168
Neurological diseases 10 (7) 13 (8) 0.645 8 (13) 3 (5) 0.114
Endocrine disorders 14 (9) 20 (12) 0.392 5 (8) 4 (7) 0.729
Gastrointestinal disorders 6 (4) 21 (13) 0.005 6 (10) 11 (18) 0.191
Urogenital disorders 4 (3) 1 (1) 0.150 5 (8) 2 (3) 0.243
Inflammatory joint disorders and
connective tissue disorders
31 (20) 44 (27) 0.179 16 (26) 13 (21) 0.523
Cancer 14 (9) 17 (10) 0.730 8 (13) 6 (10) 0.570
Mental disorders 4 (3) 7 (4) 0.428 3 (5) 2 (3) 0.648
Comorbidities (range 0–6) 1.0 (1.0) 1.2 (1.1) 0.073 1.2 (1.1) 1.5 (0.9) 0.218
Note. Mean (SD) for continuous variables and numbers (%) for categorical variables.
ART, antiresorptive treatment, a specific osteoporosis treatment comprising bisphosphonates, or selective estrogen-receptor modulators;
BMD, bone mineral density; BMI, body mass index.
* P values indicate differences between the patients with wrist fracture and controls.
† P values indicate differences between the patients with hip fracture and controls.
z Exercise more than 30 min three times a week.
y Osteoporosis was defined as a T score of r 2.5 SD.
: The numbers differs between the measures site because of some invalid measures (e.g., due to hip replacement).
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 1 0 0 – 1 1 0 71102dichotomy and each of the independent variables were entered in
the equations, one pair at a time, while retaining the other
independent variables (i.e., main effects) in the model. The level
of significance was set at 0.05.
Ethics
The study was approved by the Regional Committee for Medical
Research Ethics and by the National Data Inspectorate.Results
Demographical and Clinical Characteristics
Sociodemographical and clinical characteristics at baseline of
those participants who completed all baseline, 1-year follow-up,
and 2-year follow-up assessments are shown in Table 1. Patients
with fragility wrist fracture were more often living alone (P ¼ 0.012),
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VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 1 0 0 – 1 1 0 7 1103had fewer years of education (P ¼ 0.008), had a lower body mass
index (BMI) (P ¼ 0.049), and were more frequently classified with
osteoporosis (Po 0.001) compared with the controls. Patients with
hip fracture were more likely to live alone (P ¼ 0.045), exercise less
(P ¼ 0.033), smoke more (P ¼ 0.019), and more frequently have
osteoporosis (Po 0.001) compared with the controls.
Changes in the 15D and SF6D Scores
In the fragility wrist fracture group, significant changes for 15D
scores were found from baseline to 1- and 2-year follow-up
(Table 2). For SF-6D scores, no significant changes between base-
line and follow-up values were found. In the controls, no
significant changes in 15D or SF-6D scores were seen.
For both 15D and SF-6D scores in the fragility hip fracture
group, significant changes between baseline and follow-up values
were found for 1-year and 2-year follow-up (Table 3). In the hip
fracture controls, no significant changes in 15D and SF-6D scores
were seen. For both fracture groups and controls, no significant
changes in 15D and SF-6D scores were seen between 1- and
2-year follow-up. Because of multiple comparisons, we also
applied repeated multivariate analysis of variance on the changes
in 15D and SF-6D scores within patients and within controls, and
the same pattern persisted.
Differences in the Utility Scores between Patients with Wrist
Fractures and Controls and Patients with Hip Fractures and
Controls
At baseline, the patients with wrist fractures reported signifi-
cantly higher 15D scores than did controls (P ¼ 0.042). At 1- and
2-year follow-up, however, no significant differences between the
groups were seen (P ¼ 0.504 and 0.968, respectively). Comparing
SF-6D scores for patients and controls at baseline and at 1- and
2-year follow-up revealed no significant differences (P ¼ 0.675,
0.661, and 0.254, respectively).
The patients with hip fractures reported significantly lower
15D scores than did controls at baseline (P ¼ 0.039) and at 1- and
2-year follow-up (P o 0.001). For SF-6D scores, significant differ-
ences between hip fracture patients and controls were also found
at baseline (P ¼ 0.011) and at 1- and 2-year follow-up (Po 0.001).
Correlations between the 15D and SF-6D change scores over a
2-year period were 0.356 in patients with wrist fracture
(P o 0.001), 0.259 in controls (P ¼ 0.002), 0.624 in patients with
hip fracture (Po 0.001), and 0.353 in controls (P ¼ 0.010).
Responsiveness
ESs expressing internal responsiveness for 15D and SF-6D scores
are displayed in Table 2 and Table 3 for patients with fracture and
controls. A small change in the 15D scores in patients with wrist
fracture was seen between baseline and 1-year (ES ¼ 0.3) and 2-
year follow-up (ES ¼ 0.3). In patients with hip fractures, med-
ium changes in 15D scores between baseline and 1-year
(ES ¼ 0.6) and 2-year follow-up (ES ¼ 0.6) were seen. For wrist
fracture patients, the ES for SF-6D scores between baseline and
follow-up was 0.1 and 0.0, respectively. In hip fracture patients,
the ES for SF-6D scores between baseline and 1- and 2-year
follow-up was 0.5 and 0.4.
The Impact of a Fragility Wrist or Hip Fracture on Changes in
15D and SF-6D Scores 2 Years After Fracture
When comparing patients with wrist fracture and controls,
worsened 15D score was predicted by being a patient with wrist
fracture (B ¼ –0.016; P ¼ 0.049) and having a low BMI (B ¼ –0.002;
P ¼ 0.009). Interaction terms between pairs of each independent
variable and patients/controls (tested one pair at a time) revealed
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VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 1 0 0 – 1 1 0 71104that having a low BMD (osteoporosis) at baseline had a signifi-
cantly stronger (negative) effect on changes in HRQOL among
patients with wrist fracture than among controls. Worsened SF-
6D scores were predicted only by a low BMI (B ¼ 0.004;
P o 0.001) but not by having a wrist fracture (Table 4).
When comparing patients with hip fracture and controls,
worsened 15D scores were predicted by being a patient with hip
fracture (B ¼ 0.060; P ¼ 0.001) and having a low BMI (B ¼ 0.005;
P ¼ 0.018), while worsened SF-6D scores were predicted by being
a patient with hip fracture (B ¼ 0.095; P ¼ 0.001) and old age
(B ¼ 0.003; P ¼ 0.013) (Table 5).Discussion
To our knowledge, this is the first study that uses the utility
measures 15D and SF-6D to study changes in HRQOL in patients
with a fragility fracture at the wrist or at the hip. In our study, the
two utility instruments revealed different findings in wrist
fracture patients. A significant decrease in HRQOL in our wrist
fracture patients after 1- and 2-year follow-up was found only
when assessed by 15D but not by SF-6D. A reduction in 15D
scores took place in the first year, which remained during the
second year of follow-up. The changes in HRQOL measured by
15D seem to be attributable to the wrist fracture. This appears to
be slightly at odds with findings from previous studies, which
indicate no reduction in long-term HRQOL following a wrist
fracture [7,8]. In a previous report from this same wrist fracture
cohort, we found no significant changes in SF-36 [9]. This may
indicate that responsiveness for the 15D may be better than for
the SF-6D. In our patients with hip fractures, a decrease was seen
for both 15D and SF-6D scores. For hip fracture, the literature has
been consistent in reporting a reduction in HRQOL after hip
fracture [3,5–8,24]. From this same hip fracture cohort, we have
previously also reported a persistent long-term reduction in SF-36
scores [15].
The strength of our study is the study design comparing
patients with age- and gender-matched controls recruited from
the background population of the fracture patients. In the control
groups, for both the wrist and the hip fracture patients, no
significant changes in 15D or SF-6 D scores were found over the
2-year period.
The differences in changes after the fracture using different
generic HRQOL utility instruments might be attributed to the
nature of the health items included and the way the questions
are asked. On the other hand, most generic instruments intended
for HRQOL assessment include at least some items that focus on
physical, emotional, and social functioning, which is also the
case in the HRQOL instruments 15D and SF-6D used in the
present study [13]. The decrease in the mean 15D score 2 years
after fracture might also be partly attributed to higher 15D scores
prior to wrist fracture compared with baseline scores in the
controls. The higher 15D scores in wrist patients at baseline
might in part be explained by a tendency of a higher total
comorbidity score in the controls compared with wrist patients;
however, it was not statistically significant. A mean decrease of
0.02 in 15D scores between baseline and 1- and 2-year follow-up
might be considered as not being a clinically important differ-
ence. According to Sintonen, however, it has been documented
that a 15D score change of 0.02 to 0.03 is detectable and
recognizable for the individual [19]. Another explanation of the
decrease in 15D score over the 2-year period might be that our
findings for wrist fracture patients only is a result of random
fluctuations. We believe, however, that it is rather unlikely that
15D scores in the wrist fracture patients remained significantly
reduced not only at 1-year follow-up but also at 2-year follow-up.
Table 4 – Predictors of 2-y change in health-related quality of life (delta 15D and delta SF-6D) in patients with wrist fracture
(n ¼ 152) and controls (n ¼ 164).
Adj B 15D (95% CI) P Adj B SF-6D (95% CI) P
Demographic
Age 0.000 (0.000–0.000) 0.240 0.001 (0.001 to 0.001) 0.279
Male 0.021 (0.045 to 0.004) 0.105 0.000 (0.041 to 0.040) 0.985
Living alone 0.000 (0.017 to 0.016) 0.975 0.013 (0.014 to 0.041) 0.341
BMI 0.002 (0.004 to 0.000) 0.009 0.004 (0.008 to 0.002) 0.001
Clinical
Wrist fracture patients 0.016 (0.032 to 0.000) 0.049 0.010 (0.036 to 0.017) 0.478
Osteopenia† 0.001 (0.020 to 0.017) 0.899 0.019 (0.049 to 0.011) 0.212
Osteoporosis† 0.014 (0.037 to 0.010) 0.255 0.037 (0.078 to 0.004) 0.074
Baseline HRQOL
15D/SF-6D 0.181 (0.278 to 0.091) o0.001 0.369 (0.470 to 0.002) o0.001
R2 adj (%) 6.4 18.4
Note. Regression analyses of demographics, clinical characteristics, and 15D/SF-6D scores at baseline of changes in 15D or SF-6D scores.
Adjusted unstandardized regression coefficients, 95% CI, P values.
15D, a multiattribute utility measure, having 15 dimensions of health, and SF-6D, where 1.00 means perfect health.
BMD, bone mineral density; BMI, body mass index; CI, confidence interval; HRQOL, health-related quality of life; SF-6D, six-dimensional health
state short form (derived from short form 36 health survey).
* Age in decades.
† Osteopenia/osteoporosis at total hip and/or spine L2-L4.
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the wrist fracture patients over the 2-year period might be seen as
a sign of higher internal responsiveness for 15D than for SF-6D.
The ES of 0.3 for 15D, however, was small, and the results have
to be interpreted with caution. According to Cohen, ESs in the
range 0.2 to 0.5 should be defined as small [12,22]. In our patients
with hip fracture, the ES for 15D was also slightly higher than for
SF-6D, which further might indicate a higher responsiveness in
15D. For hip fracture patients, the ES for 15D at 2-year follow-up
was 0.6, which is defined as medium effect, whereas for SF-6D,
the ES was 0.4, which is defined as small effect according to
Cohen. In previous studies including 15D and SF-6D, Stavem et al.
[21] reported no evidence of a better responsiveness of the 15D
compared with the EQ-5D questionnaire and SF-6D in patients
with HIV/AIDS, while Kontodimopoulos et al. [25] showed thatTable 5 – Predictors of 2-y change in health-related quality of l
(n ¼ 61) and controls (n ¼ 61).
Adj B 15D (95% CI)
Demographic
Age 0.002 (0.003 to 0.000)
Male 0.000 (0.036 to 0.035)
Living alone 0.011 (0.022 to 0.043)
BMI 0.005 (0.009 to 0.001)
Clinical
Hip fracture patients 0.060 (0.094 to 0.026)
Osteopenia† 0.006 (0.046 to 0.033)
Osteoporosis† 0.041 (0.088 to 0.007)
Baseline HRQOL
15D/SF-6D 0.211 (0.387 to 0.036)
R2 adj (%) 16.6
Notes. Regression analyses of demographics, clinical characteristics, an
Adjusted unstandardized regression coefficients, 95% CI, P values.
15D, a multiattribute utility measure, having 15 dimensions of health, a
BMD, bone mineral density; BMI, body mass index; CI, confidence interval
state short form (derived from short form 36 health survey).
* Age in decades.
† Osteopenia/osteoporosis at total hip and/or spine L2–4.15D might be more sensitive in diabetic intervention compared
with the EQ-5D questionnaire and SF-6D, which they explain by 15D
comprising a richer descriptive system. Kvam et al. [26] reported an
acceptable responsiveness of 15D in patients with multiple mye-
loma, yet not as good as for the EQ-5D questionnaire and European
Organization for Research and Treatment of Cancer QLQ-30. And
with regard to SF-6D, Buitinga et al. [27] reported that the SF-6D was
more responsive than the EQ-5D questionnaire in patients with
rheumatoid arthritis. In the literature, there is no unequivocal
evidence of better or worse responsiveness of 15D compared with
SF-6D across studies within different patient groups. The better
responsiveness of 15D compared with that of SF-6D in our study
also was rather weak, and one may argue that these differences are
not of clinical relevance. Demographic and clinical characteristics
(except osteoporosis) in patients with wrist fracture all in all areife (delta 15D and delta SF-6D) in patients with hip fracture
P Adj B SF-6D (95% CI) P
0.074 0.003 (0.006 to 0.001) 0.013
0.988 0.009 (0.063 to 0.045) 0.734
0.520 0.004 (0.045 to 0.052) 0.880
0.018 0.003 (0.009 to 0.052) 0.361
0.001 0.095 (0.147 to 0.042) 0.001
0.752 0.013 (0.071 to 0.044) 0.648
0.093 0.005 (0.075 to 0.066) 0.898
0.018 0.481 (0.657 to 0.305) o0.001
28.7
d 15D/SF-6D scores at baseline of changes in 15D or SF-6D scores.
nd SF-6D, where 1.00 means perfect health.
; HRQOL, health-related quality of life; SF-6D, six-dimensional health
VA L U E I N H E A LT H 1 5 ( 2 0 1 2 ) 1 1 0 0 – 1 1 0 71106comparable with the controls, which supports previous findings
indicating that wrist fractures mostly occur in otherwise relatively
healthy middle-aged and elderly individuals, with an active life-
style, good physical and mental health, but with reduced BMD
[28–30]. And in some cases, the fracture happened just because of
bad luck. In patients with hip fracture, our findings indicate a
different pattern. Hip fracture occurs in elderly individuals char-
acterized by a large complexity in their underlying conditions,
comorbidities, and clinical histories compared with control, which
also have been seen in previous findings [31–35].
Using retrospective reports for the collection of HRQOL data
prior to fracture is a limitation of our study, because ideally such
data should have been collected before the fracture occurred. For
practical reasons, however, it is of course almost impossible to
collect HRQOL data prospectively for a population with a specific
injury, and alternative methods relying on preinjury recall have
been used in several previous trauma studies [14,36–38]. Retro-
spective evaluations can be biased by recall problems and
response shifts caused by the trauma under investigation
[13,39,40]. To minimize this problem, it is recommended that
HRQOL assessments should be performed within the shortest
possible time period after the fracture event, which was indeed
the aim in our study [12,13]. To further minimize the limitations
of our study design, the questionnaires were administered with
an instruction that the patients should report their status before
the fracture. The response options given in the 15D and SF-36 are
different in their nature [19,41–43] and might be influenced
differently by potential recall problems and response shift. The
15D asks about the response option that best describes the health
status before the fracture, while the SF-36 asks about limitations
or problems during the past 4 weeks before fracture. As pre-
viously mentioned, however, most generic instruments intended
for HRQOL assessment include at least some items that focus on
physical, emotional, and social functioning, which is also the
case in the HRQOL 15D and SF-6D instruments in this study [13].
A further potential limitation of our study is the patients who
were lost to follow-up. They were characterized by lower 15D and
SF-6D scores at baseline and a higher number of diseases.
Reduced health in patients who are lost to follow-up has been
reported in other studies as well [8] and may influence the
results. Reduced HRQOL prior to fracture might also be seen as
a potential risk factor of decreased health and death in the study
population and thereby a predictor of future objective health and
HRQOL, especially in patients with fragility hip fracture. The aim
of our study, however, was to compare the self-reported health
measures and examine the impact of fragility fractures on 15D
and SF-6D scores over a 2-year period rather than exploring their
role as predictors of objective health outcomes such as hospita-
lizations and death.
The patients included in the present study were probably
among the healthiest patients. The patients who were unwilling
to participate and thus excluded from the study we know were
older and probably less healthy than the patients included in the
study [44]. Furthermore, the patients who dropped out during the
2-year follow-up period seemed to be less healthy than the
patients who attended the 2-year follow-up [9,15]. Our findings
therefore should be interpreted with caution. On the other hand,
it seems unlikely that HRQOL in less healthy fragility fracture
patients would be influenced to a lesser extent by the fracture.Conclusions
Our findings nuance previous findings reporting no long-term
reduction in HRQOL following a fragility wrist fracture. The data
in the present study indicate that a fragility wrist fracture may
indeed have a negative impact on HRQOL. Our study confirmsthat hip fracture has a sustained, long-term negative effect on
HRQOL as assessed both by 15D and SF-6D. Furthermore, our data
indicate that 15D seems to be more responsive than SF-6D when
assessing utility and HRQOL in both types of fractures, although
the results should be interpreted with caution. This may be of
importance for health economic analyses (cost-utility analyses)
for calculation of quality-adjusted life-years in fracture patients
decision making, and for the proper interpretation of studies of
health utility and HRQOL.Acknowledgments
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